YULIYA SPENCER: Open Payments
NPI 1407227861 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,717 in 179 payments from 12 companies in 2025. Trend: 2023 $20,596 · 2024 $12,085 · 2025 $4,717
Food & beverage: $3,342Speaker / faculty: $1,375
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $1,579 |
| Neurocrine BioSciences, Inc. | 19 | $617 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $541 |
| E.R. Squibb & Sons, L.L.C. | 25 | $452 |
| Alkermes, Inc. | 15 | $291 |
| Teva Pharmaceuticals USA, Inc. | 22 | $279 |
| Vanda Pharmaceuticals Inc. | 10 | $268 |
| Otsuka America Pharmaceutical, Inc. | 12 | $216 |
| Axsome Therapeutics, Inc. | 8 | $187 |
| Lundbeck LLC | 8 | $178 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, COBENFY, FANAPT, ARISTADA, AUSTEDO XR, Auvelity.
Industry payments across AL — which companies pay providers there.
